278 related articles for article (PubMed ID: 30066303)
1. Antral follicle count recovery in women with menses after treatment with and without gonadotropin-releasing hormone agonist use during chemotherapy for breast cancer.
Sinha N; Letourneau JM; Wald K; Xiong P; Imbar T; Li B; Harris E; Mok-Lin E; Cedars MI; Rosen MP
J Assist Reprod Genet; 2018 Oct; 35(10):1861-1868. PubMed ID: 30066303
[TBL] [Abstract][Full Text] [Related]
2. Long-term hormonal contraceptive use is associated with a reversible suppression of antral follicle count and a break from hormonal contraception may improve oocyte yield.
Letourneau JM; Cakmak H; Quinn M; Sinha N; I Cedars M; Rosen MP
J Assist Reprod Genet; 2017 Sep; 34(9):1137-1144. PubMed ID: 28669055
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
[TBL] [Abstract][Full Text] [Related]
4. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
Lee DY; Park YH; Lee JE; Choi D
Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
[TBL] [Abstract][Full Text] [Related]
5. Fertility preservation in women with malignancies: the accuracy of antral follicle count collected randomly during the menstrual cycle in predicting the number of oocytes retrieved.
Filippi F; Martinelli F; Paffoni A; Reschini M; Raspagliesi F; Somigliana E
J Assist Reprod Genet; 2019 Mar; 36(3):569-578. PubMed ID: 30478807
[TBL] [Abstract][Full Text] [Related]
6. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
Tsakos E; Tolikas A; Daniilidis A; Asimakopoulos B
Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
[TBL] [Abstract][Full Text] [Related]
8. Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation.
Tran ND; Aghajanova L; Kao CN; Cedars MI; Rosen MP
Fertil Steril; 2016 Mar; 105(3):690-696. PubMed ID: 26696299
[TBL] [Abstract][Full Text] [Related]
9. What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation?
Sonigo C; Simon C; Boubaya M; Benoit A; Sifer C; Sermondade N; Grynberg M
Hum Reprod; 2016 Jul; 31(7):1493-500. PubMed ID: 27165625
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of ovarian stimulation after treatment with chemotherapy.
Chan JL; Johnson LN; Efymow BL; Sammel MD; Gracia CR
J Assist Reprod Genet; 2015 Oct; 32(10):1537-45. PubMed ID: 26400507
[TBL] [Abstract][Full Text] [Related]
11. Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials.
Nelson SM; Klein BM; Arce JC
Fertil Steril; 2015 Apr; 103(4):923-930.e1. PubMed ID: 25624196
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility.
Franco JG; Oliveira JB; Petersen CG; Mauri AL; Baruffi R; Cavagna M
Med Hypotheses; 2012 Apr; 78(4):442-5. PubMed ID: 22284634
[TBL] [Abstract][Full Text] [Related]
13. Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients.
Grynberg M; Poulain M; le Parco S; Sifer C; Fanchin R; Frydman N
Hum Reprod; 2016 Mar; 31(3):623-9. PubMed ID: 26759139
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis.
Silva C; Caramelo O; Almeida-Santos T; Ribeiro Rama AC
Hum Reprod; 2016 Dec; 31(12):2737-2749. PubMed ID: 27664208
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis.
Vitek WS; Shayne M; Hoeger K; Han Y; Messing S; Fung C
Fertil Steril; 2014 Sep; 102(3):808-815.e1. PubMed ID: 25044080
[TBL] [Abstract][Full Text] [Related]
16. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.
Partridge AH; Ruddy KJ; Gelber S; Schapira L; Abusief M; Meyer M; Ginsburg E
Fertil Steril; 2010 Jul; 94(2):638-44. PubMed ID: 19409543
[TBL] [Abstract][Full Text] [Related]
17. Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
Quinn MM; Cakmak H; Letourneau JM; Cedars MI; Rosen MP
Hum Reprod; 2017 Mar; 32(3):568-574. PubMed ID: 28122888
[TBL] [Abstract][Full Text] [Related]
18. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
Zhang Y; Ji Y; Li J; Lei L; Wu S; Zuo W; Jia X; Wang Y; Mo M; Zhang N; Shen Z; Wu J; Shao Z; Liu G
Breast Cancer Res Treat; 2018 Apr; 168(3):679-686. PubMed ID: 29332135
[TBL] [Abstract][Full Text] [Related]
19. Both in vivo FSH depletion and follicular exposure to Gonadotrophin-releasing hormone analogues in vitro are not effective to prevent follicular depletion during chemotherapy in mice.
Horicks F; Van Den Steen G; Gervy C; Clarke HJ; Demeestere I
Mol Hum Reprod; 2018 Apr; 24(4):221-232. PubMed ID: 29438534
[TBL] [Abstract][Full Text] [Related]
20. Serum antimüllerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation.
Sermondade N; Sonigo C; Sifer C; Valtat S; Ziol M; Eustache F; Grynberg M
Fertil Steril; 2019 Feb; 111(2):357-362. PubMed ID: 30527837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
